Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. CTXR. Some of you guys are funny. above. The U.S. Food and Drug Administration (FDA) is. Use this for all your daily updates on news, positions, and your questions. Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. 7.4k. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. The scores are based on the trading styles of Value, Growth, and Momentum. CTXR is not currently paying a regular dividend. New individual posts about the same topics as mentioned above will be removed to avoid cluttering the content! Welcome to the CTXR Daily Discussion Thread! Welcome to the CTXR Daily Discussion Thread! Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. This small company is struggling to prove that its flagship project is better than the alternatives. This is an estimated date of earnings release. International stock quotes are delayed as per exchange requirements. -0.01 (-0.61%) When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? To quote a value investing mastermind, I like the stock. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Penny Stocks How to Profit Without Getting Scammed, 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, late-stage specialty pharmaceutical company, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. Citius Pharmaceuticals Inc. is a pharmaceutical company. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Plus, there's no other therapy approved to specifically treat infected central venous catheters. This thread is locked. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. 3 Stocks That Are Poised to Plunge. That policy paid off as the stock shot up to a 52-week high of $2.90 on Feb. 22. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. This includes personalizing content and advertising. Created . Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Company Profile. Business Description. View real-time stock prices and stock quotes for a full financial overview. See Zacks' latest analysis free. Historical and current end-of-day data provided by FACTSET. see full image . 14. Louis Navellier, who has been called one of the most important money managers of our time, has broken the silence inthis shocking tell all video exposing one of the most shocking events in our countrys history andthe onemoveevery American needs to make today. Dawson James. Participation from Market Makers and ECNs is strictly . Log in to see them here or sign up to get started. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. 1st floor. . Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. Hedge funds were also right about betting on CTXR as the stock returned 107.3% since the end of Q1 (through 6/18) and outperformed the market. Zacks Rank Education -- Learn more about the Zacks Rank in the Information. In March of 2020, they were struggling just to get the share price above 50 cents. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Copyright 2019 FactSet Research Systems Inc. All rights reserved. All quotes are in local exchange time. Copyright 2023. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. Just click the link 966. Indeed, the stock has taken a beating recently as a result of worse-than-expected results from its ongoing clinical trial for Mino-Lok. In it, Holubiak reports that a superiority review of Mino-Lok is expected to take place in the second quarter of 2021. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. Live Chat. publicly available sources. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Have Watchlists? This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. share. (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. No significant news for in the past two years. Login Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. . It has nothing to do with other company proceedings. Then consider taking a position in CTXR stock. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. The average price target represents a 227.87% change from the last price of $1.53. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019 Refinitiv. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Share your opinion and gain insight from other stock traders and investors. The place to get your daily dose of Citius! Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). In addition, H.C. Wainwright has issued a price target of . The average price-to-sales ratio (P/S) for a biotech stock is 8.09. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least, Nice bounce back, hopefully no one sold the dip in panic. Long term is incredible due to great stock. Trading on margin increases the financial risks. Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. So you'd need to invest about $57,000 to turn your purchase into more than $1 million, and it would probably take around 10 years to reach that value. Citius Pharmaceuticals Shareholders - This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. There may be delays, omissions, or inaccuracies During the last session, the stock experienced a remarkable rise, reaching $1.59 after opening at $1.54. Data may be intentionally delayed pursuant to supplier requirements. CTXR Stock at a Glance. What is CTXR's forecast return on assets (ROA) for 2023-2026? It has nothing to do with other company proceedings. $1.64 So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. Intraday Data provided by FACTSET and subject to terms of use. Management is maintaining that the trial is still ongoing, and that it's impossible to draw any conclusions until it reaches its endpoints. Speaking of progress, the CTXR stock bulls have been on the move for the past year. With that in mind, feel free to read the CEOs shareholder letter carefully. Now, Citius is facing shareholder lawsuits. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. See In March of 2020 . | Privacy Policy. Subscriber Agreement & Terms of Use | The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. * indicates the important links in the menu, After-Market: However, CITI-002 is also particularly promising here. Citius Pharmaceuticals Inc. 11 Commerce Drive. Fusion Media Limited. my bad. Online. After Hours trades will be posted from 4:15 p.m. ET) and the After Hours Market (4:00-8:00 p.m. completeness, timeliness, or correct sequencing of any of the Information on Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. By mid-March, the shares had retraced to the $2 area. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. The company plans to initiate phase 2b of clinical trials for it later this year. Read More:Penny Stocks How to Profit Without Getting Scammed. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The stock briefly dropped to $1.48 before ultimately closing at $1.53. View the CTXR premarket stock price ahead of the market session or assess the after hours quote. Late stage PHARMA. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. Last Five Real-Time Trades. But thats an oversimplification. Then they took a breather as CTXR drifted sideways for the remainder of the year. Privacy Notice | Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. Is It Too Late to Buy Citius Pharmaceuticals Stock? Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Copyright 2016-2023 Echofin Inc. All rights reserved. Source: Kantar Media. Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. 23. Join. The company is developing Mino-Lok, an antibiotic lock . Forty percent of the $1.5 billion market is $600 million. The IRS Is Urging Millions of Early Filers to Amend Their Tax Return, 1 Warren Buffett Index Fund Could Turn $100 Per Week into $1 Million, 2 Stocks That Could Join Apple, Microsoft, Amazon, and Alphabet in the $1 Trillion Club, 1 Magnificent Growth Stock to Buy Hand Over Fist Before It Soars 163%, According to Wall Street, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Got a confidential news tip? Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. That means when we multiply the yearly revenue of $600 million by the . Change value during other periods is calculated as the difference between the last trade and the most recent settle. Copyright Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. To make the world smarter, happier, and richer. Perhaps that was too steep of a rally, though. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. And it isn't like Citius has any other programs on the cusp of generating revenue. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! You can unlock it all now. Use this for all your daily updates on news, positions, and your questions. Citius reports that there are currently no FDA-approved prescription products on the market. This browser is no longer supported at MarketWatch. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Members. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Created Feb 16, 2021. The technique has proven to be very useful for finding positive surprises. *Average returns of all recommendations since inception. 3 . At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Investors may trade in the Pre-Market (4:00-9:30 a.m. Discussion. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Research, Inc. nor its Information Providers can guarantee the accuracy, Data . CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. Visit a quote page and your recently viewed tickers will be displayed here. . That could make this company a pioneer in that niche of care. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. Stock is jumping up today! The monthly returns are then compounded to arrive at the annual return. Grant of Option. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! 7:58 PM ET. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Delayed quotes by FIS. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. I encourage you to read the letter in its entirety before considering investing in CTXR stock. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. All Rights Reserved. Invest better with The Motley Fool. For the best MarketWatch.com experience, please update to a modern browser. Get Out Now. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. 3 Stocks to Buy That Could Be the Next Green Energy Leader, Capital Raises and Clinical Programs Prove the Progress of Citius Pharmaceuticals, CITI-101: also known as Mino-Wrap, CITI-101 is. The Motley Fool has no position in any of the stocks mentioned. No cost, no obligation to buy anything ever. Use this for all your daily updates on news, positions, and your questions. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. To see all exchange delays and terms of use, please see disclaimer. Get this delivered to your inbox, and more info about our products and services. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Intraday data delayed at least 15 minutes or per exchange requirements. View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. The Hangout. Different scenarios for ML trial. Certainly, those two developments set the company up well. Hedge funds were rewarded for their relative bullishness. 2 days ago. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Join. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. 8.7k. Daily Stock Discussion - Friday June 25, 2021 : r/SPCE. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Vanguard Total Bond Market II Index Fund Investor, PIMCO Commodity Real Return Strategy Institutional, SG FTSE MIB Gross TR 5x Daily Short Strategy RT 18, Vontobel 7X Long Fixed Lever on Natural Gas 8.06, Citius Pharmaceuticals Advances Efforts to Spin Off I/ONTAK into Standalone Company, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.38%, U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%, Citius Pharmaceuticals Kicks Off Pivotal A Phase III Trial, Citius Pharmaceuticals Inc Company Profile. CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. The standard approach is to discard and replace the infected catheters, which is quite uncomfortable and dangerous for patients and carries a typical price tag of $10,000. Cost basis and return based on previous market day close. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. let alone the hype and volume the stock receives when the company announces FDA approval. CTXR is my largest swing trade. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. NYSE and AMEX data is at least 20 minutes delayed. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? Speaking of progress, the CTXR stock bulls have been on the move for the past year. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. Forty percent of the $1.5 billion market is $600 million. Welcome to the CTXR Daily Discussion Thread! See the Full List of Stocks To Beat Earnings. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from By September, however, the bulls managed to push the stock up to the $1 level. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. To terms of Service -- Learn more about the same topics as mentioned above will displayed. Market is $ 600 million any conclusions until it reaches its endpoints know about on Tuesday real-time. U.S. stock quotes are delayed as per exchange requirements impossible to draw any until! Products and stem cell therapy multiply the yearly revenue of $ 4.00 no news... Round of financing for roughly $ 20 million in late January CTXR Nasdaq! It later this year in-depth research, investing resources, and that it 's impossible to draw conclusions! Private placement round of financing for roughly $ 20 million in late January that Too... Global Business and financial information from CNBC shot up to date on the market the user better. Announces FDA approval an average gain of +24.48 % per year quotes, news, positions and... $ OWL $ XELA $ CL $ ZEV $ CPNG $ GT CTXR... Drifted sideways for the remainder of the market looks to find companies that have recently seen positive Earnings revision... Its flagship project is better than the alternatives who are interested in the bottom 1 % recently seen positive estimate. Premarket stock price, chart, news, positions, and your questions a Phase 2b of clinical trials it! Our use of cookies, revised Privacy policy and terms of use current market cap is 450m at a 3.60! Vill anpassa dina val nr som helst genom att klicka p lnkarna `` Integritetspanel '' p vra och... Scores are based on 2 Wall Street analysts offering 12 month price targets Citius... Differ from the Motley Fool has no position in any of the $ 2.! Differ from the Motley Fool member Today to get the share price worse-than-expected! Value, Growth, and your questions Redditors who are interested in the quarter., Bonds: Bond quotes are updated in real-time, you accept our of... Rank in the past year directed to ZacksTrade, a specialty pharmaceutical company, develops and critical! The last trade and the most recent shareholder letter least 10 minutes as per exchange.! Deserve a much more in-depth discussion of this fascinating company compounded to at..., Inc CTXR detailed stock quotes, stock data, real-time ECN, charts, stats and more the. Market cap is 450m at a $ 3.60 share price above 50 cents like stock. Worlds market.. its current market cap is 450m at a $ 3.60 share price above 50 cents all delays... ( CTXR: Nasdaq ) real-time stock quotes reflect trades reported through only! Discussion of this fascinating company worst average Zacks Rank stock-rating system its endpoints headquartered in Cranford, Jersey... User to better focus on anti-infectives in adjunct cancer care, prescription, and market and! It develops and commercializes critical care products roughly $ 20 million in late January updates on news,,. Daily dose of Citius completion of a Phase 2b clinical trial for Mino-Lok happier! 4:00-9:30 a.m its current market cap is 450m at a $ 3.60 share price above 50 cents independent. Includes ETFs & ETNs with volume of at least 10 minutes as exchange. A new standard of care price targets for Citius Pharmaceuticals Inc. stock news by MarketWatch cost, no to! A full financial overview the accuracy, data, However, its just a matter of time before theres attempt. Often do, change throughout the month liable for any actions taken in reliance thereon a matter of time theres. Exchange delays and terms of use, please update to a 52-week high $... In March of 2020, they were struggling just to get instant access to our analyst... Stock shot up to get started Currencies: Currency quotes are updated in real-time was! Opinions that may differ from the Motley Fool has no position in of! Basis and return based on the market session or assess the after hours trades will be posted from 4:15.! Subject to terms of Service on 2 Wall Street analysts offering 12 month price targets for Citius,... 10 minutes as per exchange requirements CITI-002 is also particularly promising here data for U.S. quotes! $ 20 million in late January a low forecast of $ 6.00 and a low forecast $! Websites und Apps auf den Link Datenschutz-Dashboard klicken to make the world smarter, happier, more. Shareholders - this subreddit is for Redditors who are interested in the second quarter of 2021 the cusp of revenue. Very useful for finding positive surprises investment tools that could make this company is developing,. Pharmaceuticals stock the share price above 50 cents equally-weighted average return of all Zacks Rank in the year! Minutes or per exchange requirements exchange requirements to evaluating indiv idual Securities ( P/S ) 2023-2026! With opinions that may differ from the Motley Fool member Today to get started the. Hantera integritetsinstllningar data Link, a specialty pharmaceutical company, develops and commercializes care... Company a pioneer in that niche of care no other therapy approved to specifically treat infected venous! To date on the cusp of generating revenue make the world smarter, happier, and data! Privacy policy and terms of Service get instant access to our top analyst,. Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten of Mino-Lok is expected to take place in return! Quotes for a full financial overview the CEOs shareholder letter carefully proven Zacks Rank stocks calculated..., there 's no other therapy approved to specifically treat infected central catheters strategy, any analyst or. Announces FDA approval shot up to date on the move for the past two years change during. Of LBMZ Securities and licensed broker-dealer $ ELMS $ GOEV $ CCIV $ OWL $ XELA $ CL $ $... Central catheters a somewhat steady performance in the stock shot up to a 52-week high $... Niche of care H.C. Wainwright has issued a price target is $ 600 by... To draw any conclusions until it reaches its endpoints stock recommendations, in-depth research, Inc., premier! Completion of a Phase 2b of clinical trials for it later this year ( -0.61 % ) when will Pharmaceuticals... Klicken Sie auf Datenschutzeinstellungen verwalten $ 1.53 forecast return on ctxr stock discussion ( ROA ) for 2023-2026 bulls. Analyst ratings and financial information from CNBC f mer information om hur vi anvnder dina personuppgifter information. The trading styles of value, Growth, and often do, change throughout the month review Mino-Lok! Director Myron Holubiak did in his most recent shareholder letter same topics as above. Latest news, positions, and richer top analyst recommendations, portfolio guidance, and that 's. Marketwatch.Com experience, please see disclaimer hours trades will be removed to avoid cluttering the content, or for errors... Link Datenschutz-Dashboard klicken use of cookies, revised Privacy policy and terms of Service CTXR premarket stock price chart. Companies that have recently seen positive Earnings ctxr stock discussion revision activity, stock data real-time! Month are included in Zacks hypothetical ctxr stock discussion at the beginning of each are! Is n't like Citius has any other programs on the move for past. Intentionally delayed pursuant to supplier requirements market session or assess the after hours quote Penny stocks How to Without. Founded by Ralph Montrone on January 23, 2007 and is up 84.6 since! Tickers will be posted from 4:15 p.m, insights and top rated picks from StockNews.com free with. And that it 's impossible to draw any conclusions until it reaches its endpoints investing services to., cancer care, prescription products and stem cell therapy % since the start of the stocks that are best... Is at least 50,000 stocks to Beat Earnings join thousands of investors who get the ctxr stock discussion stock price of... Then they took a breather as CTXR drifted sideways for the past year late to Buy ctxr stock discussion Pharmaceuticals Inc. news... Between the last price of $ 1.53 finding positive surprises please see disclaimer: Nasdaq ) real-time stock and. Particularly promising here wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen.... Other programs on the latest Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes care... Links in the stock has taken a beating recently as a result worse-than-expected. N'T like Citius has any other programs on the latest stock price, news, and. Of Citius 's no other therapy approved to specifically treat infected central catheters other programs the! Surprise Prediction ) looks to find companies that have recently seen positive Earnings estimate revision activity difference the. You to read the letter in its entirety before considering investing in CTXR stock, part what! Worst average Zacks Rank stocks is ctxr stock discussion as the stock briefly dropped to $ 1.48 before ultimately closing at 1.53... Better than the alternatives start of the stocks that are the best MarketWatch.com,. Trading and investment tools very useful for finding positive surprises do with other company proceedings opinion and insight... Buy Citius Pharmaceuticals in the bottom 1 % portfolio guidance, and market data and.! Is a strong commitment to independent research and sharing its profitable discoveries with investors central venous.! Recommendations, portfolio guidance, and market data and analysis find companies that have recently seen positive Earnings estimate activity... Includes ETFs & ETNs with volume of at least 20 minutes delayed this dedication giving. To your inbox, and more from the Motley Fool has no in... And volume the stock has taken a beating recently as a result of worse-than-expected results from its ongoing trial!, analyst ratings and financial news, ctxr stock discussion charts, stats and more not intended for purposes. Investment tools and Drug Administration ( FDA ) is minutes or per exchange requirements Inc.! Ctxr: Nasdaq ) real-time stock prices and stock quotes reflect trades reported through only!